Literature DB >> 27193993

Deferasirox AUC efficacy cutoff and role of pharmacogenetics.

S Allegra1, J Cusato1, S De Francia2, D Massano3, A Piga3, A D'Avolio4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27193993     DOI： 10.1007/s00228-016-2070-9

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  5 in total

1.  A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients.

Authors:  Silvia De Francia; Davide Massano; Francesca Maria Piccione; Elisa Pirro; Silvia Racca; Francesco Di Carlo; Antonio Piga
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2012-03-06       Impact factor: 3.205

2.  Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness.

Authors:  J Cusato; S Allegra; D Massano; S De Francia; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2014-10-28       Impact factor: 3.550

3.  Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats.

Authors:  Gerard J M Bruin; Thomas Faller; Hansjörg Wiegand; Alain Schweitzer; Hanspeter Nick; Josef Schneider; K-Olaf Boernsen; Felix Waldmeier
Journal:  Drug Metab Dispos       Date:  2008-09-05       Impact factor: 3.922

4.  Deferasirox pharmacokinetics in patients with adequate versus inadequate response.

Authors:  Deborah Chirnomas; Amber Lynn Smith; Jennifer Braunstein; Yaron Finkelstein; Luis Pereira; Anke K Bergmann; Frederick D Grant; Carole Paley; Michael Shannon; Ellis J Neufeld
Journal:  Blood       Date:  2009-09-01       Impact factor: 22.113

5.  High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients.

Authors:  Marc Delord; Philippe Rousselot; Jean Michel Cayuela; François Sigaux; Joëlle Guilhot; Claude Preudhomme; François Guilhot; Pascale Loiseau; Emmanuel Raffoux; Daniela Geromin; Emmanuelle Génin; Fabien Calvo; Heriberto Bruzzoni-Giovanelli
Journal:  Oncotarget       Date:  2013-10
  5 in total
  3 in total

1.  Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes.

Authors:  S Allegra; J Cusato; S De Francia; A Arduino; F Longo; E Pirro; D Massano; A De Nicolò; A Piga; A D'Avolio
Journal:  Pharmacogenomics J       Date:  2017-11-21       Impact factor: 3.550

2.  ABCC2 c.-24 C>T single-nucleotide polymorphism was associated with the pharmacokinetic variability of deferasirox in Chinese subjects.

Authors:  Kangna Cao; Guanghui Ren; Chengcan Lu; Yao Wang; Yanan Tan; Jing Zhou; Yongjie Zhang; Yang Lu; Ning Li; Xijing Chen; Di Zhao
Journal:  Eur J Clin Pharmacol       Date:  2019-11-01       Impact factor: 2.953

3.  Ethnogeographic and inter-individual variability of human ABC transporters.

Authors:  Qingyang Xiao; Yitian Zhou; Volker M Lauschke
Journal:  Hum Genet       Date:  2020-03-23       Impact factor: 4.132
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.